Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662305 · ClinicalTrials.gov registry record · Phase 2
Kick-Nic! Youth Quit Vaping App
A Phase 2 study of Nicotine Vaping, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 306
- Enrollment target
- 1
- Study location
NCT06662305: Recruiting Phase 2 study of Nicotine Vaping, sponsored by Yale University.
NCT06662305 is a Phase 2 study of Nicotine Vaping that is actively recruiting participants, run by Yale University. The registered enrollment target is 306 participants, roughly in line with the 289-participant average among 5 other Nicotine Vaping trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06662305, a Phase 2 study of Nicotine Vaping, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 306 participants
- Enrollment target
- 1
- Study location
Study Summary
High school students who want to quit vaping will be randomized to receive the Kick-Nic! app or a control NCI website to determine the efficacy of the app for vaping cessation. Participants will be screened for eligibility, then go through an 8 week treatment period where they will be given access to use the Kick-Nic! app or referred to the NCI Quit Vaping website. This will be followed by 1, 2, 3, and 6 month follow up visits. Qualitative interviews with participants and school staff will also be conducted to obtain feedback on the app and best ways to implement/disseminate the app. Abstinence rates will be assessed biweekly during treatment including at end of treatment (EOT), and then at 1, 2, 3 and 6 month follow ups (FU). Biochemical verification (salivary cotinine \< 30 ng.ml) of self-reports of abstinence will be conducted at EOT and 6-month FU.
Primary Outcome
Timeline Follow Back (self-report) determining 7-day point prevalence of e-cigarette use confirmed by saliva cotinine \<30ng/mL at 6 month follow up visit.
Conditions Studied
Interventions
- BEHAVIORAL Kick-Nic! mobile phone application
- BEHAVIORAL NCI Quit Vaping website
Study Locations (1)
Connecticut
- Yale University School of Medicine (Connecticut Mental Health Center) - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2025-01-16 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 2 |
What NCT06662305 shows while recruiting
NCT06662305 is an interventional study that assigns participants to a tested intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 289-participant average among 5 other Nicotine Vaping trials with a reported enrollment target.
The record links to 1 condition, with Nicotine Vaping appearing as the primary indexed condition, and to 2 interventions - of which Kick-Nic! mobile phone application is the first listed.
NCT06662305 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06662305 about?
NCT06662305 is a clinical study titled "Kick-Nic! Youth Quit Vaping App". High school students who want to quit vaping will be randomized to receive the Kick-Nic! app or a control NCI website to determine the efficacy of the app for vaping cessation. Participants will be screened for eligibility, then go through an 8 week treatment period where they will be given access t...
What is the current status of trial NCT06662305?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 306 participants. The study started on 2025-01-16. Estimated completion is 2029-08-31.
What conditions does trial NCT06662305 study?
This clinical trial studies the following conditions: Nicotine Vaping.
What interventions are being tested in trial NCT06662305?
The interventions under investigation include: Kick-Nic! mobile phone application (BEHAVIORAL), NCI Quit Vaping website (BEHAVIORAL).
Who is sponsoring clinical trial NCT06662305?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06662305 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Vaping
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
RECRUITING · NA
-
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
RECRUITING · Phase 1
-
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
RECRUITING · Phase 1
-
Nicotine Flux, a Potentially Powerful Tool for Regulating Nicotine Delivery From Electronic Cigarettes
COMPLETED · NA
-
Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
- NCT06057337 · 306 participants · NA
Families With Pride ("Familias Con Orgullo").
- NCT06498635 · 306 participants · Phase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI